Patents by Inventor Mark T. Bilodeau

Mark T. Bilodeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted imidazoles having cytokine inhibitory activity
    Patent number: 5859041
    Abstract: Compounds represented by formula I: ##STR1## are disclosed. .sup.AR represents an aromatic group containing 6-10 atoms; and ##STR2## represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom. A pharmaceutical composition is also included. Methods of treating cancer and cytokine mediated diseases are also included.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: January 12, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, David A. Claremon, John W. Butcher, Mark T. Bilodeau
  • Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
    Patent number: 5708163
    Abstract: The present invention provides a process for synthesizing a compound having the structure: ##STR1## wherein R is H, as well as related oligosaccharides useful as a vaccine for inducing antibodies to human breast cancer cells in an adjuvant therapy therefor.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: January 13, 1998
    Assignee: Sloan-Kettering Institute of Cancer Research
    Inventors: Samuel J. Danishefsky, Mark T. Bilodeau, Shuang Hua Hu, Tae Kyo Park, John T. Randolph, In Jong Kim, Philip O. Livingston